Vistagen Therapeutics Faces Class Action Lawsuits Over Allegations of Misleading Clinical Trial Results

### Vistagen Therapeutics Faces Legal Scrutiny Amid Class Action Lawsuits

Vistagen Therapeutics, Inc. is currently navigating legal tumult, having been targeted by two separate class action lawsuits related to allegations of misleading investors regarding its clinical trial results for the drug fasedienol. These legal actions, initiated by the Schall Law Firm and DJS Law Group, focus on claims that the company breached the Securities Exchange Act of 1934. Investors who acquired Vistagen shares between April 1, 2024, and December 16, 2025, are urged to join the lawsuits by the looming March 16, 2026, deadline.

The lawsuits assert that Vistagen overstated the positive outcomes of the PALISADE-2 Phase 3 trial for fasedienol, suggesting that the drug would be successful while minimizing disclosure of potential risks. This alleged misrepresentation has been said to mislead shareholders, resulting in significant financial loss as revelations about the trial's unfavorable results came to light. The claims imply that Vistagen's management may have fostered an environment that led to the inflation of investor expectations, putting the company’s integrity and future endeavors in jeopardy.

While the class actions are still pending certification, they reflect rising concerns within the pharmaceutical sector surrounding the accuracy of clinical trial disclosures. As Vistagen's development of fasedienol aims to address critical mental health conditions such as anxiety and depression, investor confidence is integral. Settling the allegations may not only affect the company's financial standing but also its reputation in an industry known for high-stakes innovation and rigorous regulatory scrutiny.

In a related note, the competitive landscape for mental health therapeutics is intensifying. With other companies such as Helus Pharma also facing setbacks in clinical trials, the pressure mounts on firms like Vistagen to not only meet clinical efficacy standards but also to maintain transparency with investors. Amid rising anxiety disorders worldwide, the potential market for effective treatments remains optimistic, making the outcomes of these legal entanglements particularly impactful.

Stakeholders are urged to closely monitor the developments surrounding these lawsuits that could reshape Vistagen's trajectory. As legal experts assess the ramifications of the class actions, companies within the therapeutic space may also need to reassess their strategies for investor communications and clinical trial disclosures to avoid similar challenges in the future.